• Verastem scheduled an investor webcast for Oct. 14, 2026 to present new clinical data for VS-7375 in KRAS G12D cancers.
• Results will be presented in the future, with initial efficacy and updated safety and tolerability from the ongoing TARGET-D program.
• Management framed VS-7375 as a potential best-in-class oral inhibitor, targeting pancreatic, lung, and colorectal tumors.
• The update builds on clinical findings already presented in June 2026, moving toward a broader cross-tumor assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609080730BIZWIRE_USPR_____20260908_BW273196) on September 08, 2026, and is solely responsible for the information contained therein.